TORONTO, March 19, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury…


Previous articleNovamind Partners with Merck for New Treatment-Resistant Depression Trial
Next articlePTSF51 – Miracle Cures, Money, and Standing on the Shoulders of Giants